-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Graves' Ophthalmopathy Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Myasthenia Gravis Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Demyelinating Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Satralizumab in Demyelinating Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Demyelinating Diseases Drug Details: Satralizumab (Enspryng) is a humanized monoclonal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inebilizumab in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inebilizumab in Myasthenia Gravis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inebilizumab in Myasthenia Gravis Drug Details: Inebilizumab-cdon (Uplizna, Xinyue) is a CD19-directed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1 in Xerostomia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-AQP1 in Xerostomia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AAV-AQP1 in XerostomiaDrug Details:AAV-AQP1 is under development for the treatment of xerostomia resulting from...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Satralizumab in Autoimmune Encephalitis (Post-Infectious)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Satralizumab in Autoimmune Encephalitis (Post-Infectious) Drug Details: Satralizumab (Enspryng) is a humanized monoclonal antibody. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eculizumab in Subarachnoid Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eculizumab in Subarachnoid Hemorrhage report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eculizumab in Subarachnoid Hemorrhage Drug Details: Eculizumab (Soliris) is a humanized monoclonal...
-
Product Insights
Alexion Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Alexion Pharmaceuticals Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Alexion Pharmaceuticals Inc (Alexion) discovers, develops, and markets therapies based on complement biology and inhibition for rare diseases. Deep understanding of rare disease enables the company to innovate and enter new areas, where there is a great unmet medical need. The company’s portfolio spans complement inhibitors for the treatment of patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis...
-
Product Insights
Net Present Value Model: Uplizna
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Uplizna Drug Details Inebilizumab-cdon (Uplizna, Xinyue)...
-
Product Insights
Net Present Value Model: Xinyue
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Xinyue Drug Details Inebilizumab-cdon (Uplizna, Xinyue)...